Press Releases

March 23, 2023
Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement 

November 7, 2022
Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured at SITC 2022 

September 20, 2022
Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY159

May 26, 2022
Pionyr Immunotherapeutics’ Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumors Featured at ASCO 2022

May 3, 2022
Pionyr Immunotherapeutics Adds Three Leading Oncology Researchers and Drug Developers to Scientific Advisory Board

March 22, 2022
Pionyr Immunotherapeutics Presents on Third Myeloid-Directed Therapeutic Program at Keystone Symposium

March 8, 2022
Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314

June 22, 2021
Pionyr and Abcam Extend Partnership to Evaluate TREM2-Expressing Cells in Cancer Patients

March 29, 2021
Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development

November 18, 2020
Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314

June 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

August 27, 2019
Pionyr Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages

July 10, 2018
Pionyr Immunotherapeutics and ProBioGen Initiate a Second Immuno-Oncology Contract Development and Manufacturing Project

December 13, 2017
Pionyr Immunotherapeutics Completes $62 million Series B Financing to Advance Antibody-Based Therapeutics Targeting the Tumor Microenvironment

January 4, 2017
Pionyr Immunotherapeutics Closes Financing with Focus on Developing Antibody-based Immuno-oncology Therapeutics